Full-Time

VP – Regulatory Affairs

Confirmed live in the last 24 hours

BridgeBio

BridgeBio

501-1,000 employees

Develops medicines for genetic diseases

Biotechnology
Healthcare

Compensation Overview

$305k - $365kAnnually

+ Performance Bonus + Equity

Expert

San Francisco, CA, USA

Hybrid position requiring in-office presence.

Category
Risk & Compliance
Legal & Compliance
Requirements
  • Bachelor's degree in scientific field required. Advanced degree (MD, PhD, PharmD, MS) preferred
  • A minimum of 15 years of relevant pharmaceutical/biotechnology regulatory affairs experience in the pharmaceutical industry, including experience leading a Regulatory Affairs group
  • Well versed in drug development process and regulatory requirements, as well as a good understanding of the underlying science
  • Strong attention to detail
  • Excellent written and verbal communication skills
  • Excellent project management skills, with ability to manage multiple projects and prioritize appropriately
  • Ability to rapidly understand & analyze complex problems/situations
  • Ability to lead teams under tight timelines and be willing to contribute significantly to day-to-day operations as needed
  • Comfort in a team environment
  • Strong interpersonal skills and the ability to effectively work with others.
  • Ability to influence without authority, lead change
  • Ability to solicit information, persuade others, and shape outcomes.
  • Experience working with all levels of management and consulting with key business stakeholders (internal and external)
Responsibilities
  • Provide leadership in creating and executing proactive regulatory strategies for product development, approval and registration
  • Apply knowledge of global quality/regulatory standards and guidelines to ensure requirements are met across programs
  • Partner with internal senior leadership to align closely on cross-functional global regulatory plans and company’s short and long-term strategic objectives
  • Take full ownership of relevant regulatory submission deliverables
  • Provide leadership and oversight of the preparation of all critical global regulatory submissions (from pre-IND to post-marketing) to the FDA, EMA, and other global health authorities
  • Represent regulatory in senior management discussions and present strategies, recommendations, and risks accordingly
  • Work at both high-level strategic and hands-on in leading a nimble team

BridgeBio Pharma develops medicines specifically for genetic diseases, focusing on conditions with well-understood genetic causes. The company operates using a decentralized subsidiary model, where each subsidiary concentrates on creating therapies for particular diseases while sharing central resources. This structure enhances efficiency and allows for the simultaneous advancement of multiple drug programs. BridgeBio utilizes advancements in genome sequencing and molecular biology to identify and develop effective treatments. Their goal is to create significant therapeutic improvements by targeting diseases at their genetic source. The company generates revenue through drug development, licensing agreements, and partnerships, with a diverse pipeline of over 15 drug programs aimed at 20 different genetic diseases. Their culture promotes independent thinking and transparency, enabling quick, data-driven decisions that enhance their drug development process.

Company Stage

IPO

Total Funding

$704.4M

Headquarters

Palo Alto, California

Founded

2014

Growth & Insights
Headcount

6 month growth

28%

1 year growth

59%

2 year growth

97%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments, such as the $46.84 million from Norges Bank and $200 million for the oncology spinout, indicate strong financial backing and growth potential.
  • The launch of BridgeBio Oncology Therapeutics with $200 million in funding highlights the company's commitment to advancing cancer treatments, particularly KRAS inhibitors.
  • Equity grants to new employees under the Amended and Restated 2019 Inducement Equity Plan demonstrate BridgeBio's commitment to attracting and retaining top talent.

What critics are saying

  • The competitive landscape in genetic disease therapies and oncology is intense, with numerous companies vying for market share.
  • The decentralized subsidiary model, while efficient, may lead to challenges in maintaining cohesive strategic direction and operational alignment.

What makes BridgeBio unique

  • BridgeBio's decentralized subsidiary model allows for focused and efficient drug development across multiple genetic diseases simultaneously, unlike traditional centralized biopharma companies.
  • The company's emphasis on genetic diseases with well-understood causes enables targeted and potentially more effective therapies, setting it apart from competitors with broader, less focused pipelines.
  • BridgeBio's robust pipeline of over 15 drug programs targeting 20 different genetic diseases showcases its diversified approach, reducing the traditional biopharma process timeline.

Help us improve and share your feedback! Did you find this helpful?